Valuation: Verastem, Inc.

Market Cap 629M 545M 511M 466M 876M 60.03B 890M 6.01B 2.35B 30.06B 2.36B 2.31B 100B P/E 2026 *
-4.33x
P/E 2027 * -5.97x
Enterprise Value 671M 582M 545M 497M 934M 64.03B 949M 6.41B 2.51B 32.06B 2.52B 2.47B 107B EV / Sales 2026 *
5.77x
EV / Sales 2027 * 2.32x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.42%
1 week+18.40%
Current month+19.83%
1 month+25.68%
3 months+50.11%
6 months+19.01%
Current year-9.97%
1 week 6.02
Extreme 6.02
7.18
1 month 5.28
Extreme 5.28
7.18
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.42%+18.40%-15.35%-29.15% 629M
-0.73%+7.82%+73.81%+102.34% 70.1B
+0.21%+1.17%+38.45%+66.83% 54.93B
-0.22%+33.59%+8.43%+489.75% 28.89B
+0.04%+10.49%+48.44%+7.45% 23.9B
-0.06%+0.61%-16.45%-13.26% 23.3B
-1.37%+7.87%+251.71%+464.53% 18.41B
-0.37%+8.10%+41.15%-19.96% 18.77B
-0.57%+3.44%+25.60%+619.86% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.48B
Average -0.63%+9.38%+48.86%+182.25% 26.75B
Weighted average by Cap. -0.42%+9.45%+54.29%+167.00%

Financials

2026 *2027 *
Net sales 116M 101M 94.53M 86.22M 162M 11.11B 165M 1.11B 435M 5.56B 437M 428M 18.54B 181M 157M 147M 134M 252M 17.28B 256M 1.73B 676M 8.65B 680M 665M 28.84B
Net income -166M -144M -135M -123M -231M -15.82B -234M -1.58B -619M -7.92B -623M -609M -26.42B -157M -136M -127M -116M -219M -14.98B -222M -1.5B -586M -7.5B -590M -577M -25.01B
Net Debt 41.9M 36.3M 34.01M 31.02M 58.33M 4B 59.22M 400M 156M 2B 157M 154M 6.67B -210M -182M -170M -155M -292M -19.99B -296M -2B -782M -10.01B -787M -770M -33.38B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
12/08/26 USD 6.950 -1.42% 1,263,817
11/08/26 USD 7.050 +3.83% 2,087,689
10/08/26 USD 6.790 +0.74% 2,298,110
07/08/26 USD 6.740 +14.04% 4,319,009
06/08/26 USD 5.910 +0.68% 2,189,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.950USD
Average target price
14.75USD
Spread / Average Target
+112.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock